Key result
Mobile health apps cut MACE risk ~32% vs control in coronary heart disease.
Why the study?
Mobile health applications have gained significant popularity and widespread use among patients with CHD, but their effects on clinical outcomes and health behaviors needed evaluation.
Do mobile health apps reduce MACEs and readmissions and improve health behaviors in patients with coronary heart disease?
Meta-Analysis
Do mobile health apps reduce MACEs and readmissions and improve health behaviors in patients with coronary heart disease?
Relative Risk: 0.68 (95% CI 0.48–0.97)
p-value: p=0.03
Mobile health applications significantly reduce the incidence of MACEs and hospital readmissions, while improving medication adherence, lipid profiles, and psychological well-being in patients with coronary heart disease.
Supports incorporating mobile health apps into coronary heart disease care; extends RCT evidence with pooled confirmation of MACE reduction.
Objective: Mobile health applications (apps) have gained significant popularity and widespread utilization among patients with coronary heart disease (CHD). The objective of this study is to evaluate the effects of mHealth apps on clinical outcomes and health behaviors in patients with CHD. Methods: Databases were searched from inception until December 2023, including Cochrane Library, PubMed, EMBASE, Web of Science, CINAHL, China National Knowledge Infrastructure (CNKI), Chinese BioMedical Literature Service System (SinoMed), Wanfang Data, China Science and Technology Journal Database (VIP), for randomized controlled trials (RCTs) regarding the effectiveness of mHealth apps in patients with CHD. Two researchers conducted a comprehensive review of the literature, extracting relevant data and evaluating each study's methodological quality separately. The meta-analysis was performed utilizing Review Manager v5.4 software. Results: > 0.05). Conclusion: Mobile health apps have the potential to lower the incidence of major adverse cardiac events (MACEs), readmission rates, and blood lipids in patients with CHD. They can also help enhance cardiac function, promote medication adherence, and alleviate symptoms of anxiety and depression. To further corroborate these results, larger-scale, multi-center RCTs with longer follow-up periods are needed.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2024) conducted a meta-analysis in Coronary heart disease (CHD). Mobile health applications (mHealth apps) vs. Control (usual care) was evaluated on Incidence of major adverse cardiac events (MACEs) (RR 0.68, 95% CI 0.48-0.97, p=0.03). Mobile health app interventions significantly lowered the incidence of major adverse cardiac events by 32% (RR 0.68, 95% CI 0.48-0.97, p=0.03) compared to control groups in patients with coronary heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: